Compare PZZA & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PZZA | GERN |
|---|---|---|
| Founded | 1984 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 1995 | 1996 |
| Metric | PZZA | GERN |
|---|---|---|
| Price | $20.72 | $1.31 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 3 |
| Target Price | ★ $45.00 | $2.17 |
| AVG Volume (30 Days) | 1.2M | ★ 8.8M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.25% | N/A |
| EPS Growth | N/A | ★ 51.85 |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $2,068,421,000.00 | $1,065,000.00 |
| Revenue This Year | N/A | $26.91 |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | $44.70 | ★ N/A |
| Revenue Growth | ★ 14.07 | N/A |
| 52 Week Low | $20.53 | $1.04 |
| 52 Week High | $55.74 | $2.01 |
| Indicator | PZZA | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 34.67 | 41.49 |
| Support Level | N/A | $1.24 |
| Resistance Level | $24.25 | $1.46 |
| Average True Range (ATR) | 0.77 | 0.08 |
| MACD | 0.09 | -0.02 |
| Stochastic Oscillator | 35.44 | 10.71 |
Papa John's International Inc operates and franchises pizza delivery and carryout restaurants and, in certain international markets, dine-in and delivery restaurants. It has four defined reportable segments: Domestic Company-owned restaurants, North America franchising, North America commissaries, and International. The company derives maximum revenue from North America commissaries segment. The North America commissaries segment consists of the operations of its regional dough production and product distribution centers in the United States and Canada and derives its revenues principally from the sale and distribution of food and paper products to Domestic Company-owned and franchised restaurants in the United States and Canada.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.